Full Text View
Tabular View
No Study Results Posted
Related Studies
Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer (NE2)
This study has been completed.
Study NCT00167648   Information provided by University of Washington
First Received: September 9, 2005   Last Updated: January 15, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cancer
Prostate Neoplasms
Additional conditions recognized in this trial
Neoplasms
Prostatic Neoplasms
More general conditions related to this trial
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
Leuprolide or goserelin
Transdermal estradiol
Additional drug interventions recognized in this trial
Androgens
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Goserelin
Leuprolide
Polyestradiol phosphate
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Contraceptive Agents
Contraceptive Agents, Female
Estrogens
Fertility Agents
Fertility Agents, Female
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Sponsors listed in this trial
University of Washington
Pacific Northwest SPORE (Specialized Projects in Oncology Research Excellence)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services